Integra LifeSciences Reports 3Q18 Revenue

Integra LifeSciences lowered their organic revenue growth goal for the year in part due to disappointing performance in their orthopaedic business. Within the segment, growth in the U.S. ankle and shoulder product lines was not enough to offset mid-teens decline in the lower extremity fixation portfolio.

The recently completed expansion of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us